CD94, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD94, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD94, Human |
| Clone | REA113 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | PE-Vio 770 conjugate |
| Size | 100 tests in 200 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD94 Antibody, anti-human, PE-Vio® 770, REAfinity™. The clone REA113 recognizes CD94, an approximately 45 kDa, single-pass type II transmembrane protein, which belongs to the C-type lectin superfamily. CD94 associates covalently with NKG2 family members and forms disulfide bonded heterodimers. CD94-NKG2 receptors bind HLA-E, the non-classical MHC class Ib molecule. Depending on the associated NKG2 member, CD94-NKG2 heterodimer transmits either activating or inhibitory signal. For, e.g, via immunoreceptor tyrosine based-inhibitory motifs (ITIMs) containing NKG2A, CD94-NKG2A heterodimers inhibit NK cell cytotoxicity. Besides NK cells, expression of CD94-NKG2 heterodimers is also shown on NK-T cells and a small percentage of CD8 cells in mice, where the crosslinking of CD94-NKG2 was shown to reduce the level of spontaneous apoptosis. | Additional information: Clone REA113 displays negligible binding to Fc receptors. | |
| Immunogen | n/a |
| Other Names | KLRD1, Kp43 |
| Gene, Accession # | Gene ID: 3824 |
| Catalog # | 130-123-884 |
| Price | $370 |
| Order / More Info | CD94, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Gunturi, A. et al. (2003) Preferential survival of CD8 T and NK cells expressing high levels of CD94. J Immunol 170: 1737-1745. | Braud, V. M. et al. (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (6669): 795-799. | Brooks, A. G. et al. (1997) NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J. Exp. Med. 185: 795-800. | Jeffery, H. et al. (2017) Human intrahepatic ILC2 are IL-13positive amphiregulinpositive and their frequency correlates with model of end stage liver disease score. PLoS One 12 (12): e0188649. | Wolpert, F. et al. (2015) Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS One 10 (10): e0139603. | Cante-Barrett, K. et al. (2017) Loss of CD44dim expression from early progenitor cells marks T-cell lineage commitment in the human thymus. Front Immunol 8: 32. | Soldierer, M. et al. (2022) Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies, Front Immunol 13: doi: 10.3389/fimmu.2022.847008. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies